SCHEMBL2579393

SCHEMBL2579393

CCN(CC)CCN1C(=O)C(O)(c2ccccc2Cl)c2c(OC)cc(C(N)=O)cc21

nearest known ligand 0.74

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 14/20 0.74
TP53 P04637 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.41
SCN9A Q15858 2/20 0.39
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2580978 0.88 GHSR (0.81) GHSRTP53POLB
SCHEMBL2581094 0.88 GHSR (0.78) GHSRTP53POLBMAPT
SCHEMBL2578797 0.88 GHSR (0.78) GHSRTP53POLBMAPT
SCHEMBL6180161 0.88 GHSR (0.77) GHSRTP53POLBMAPT
SCHEMBL6376444 0.85 GHSR (1.00) GHSRPOLB
SCHEMBL2572828 0.85 GHSR (1.00) GHSRPOLB
SCHEMBL29966946 0.85 GHSR (1.00) GHSRPOLB
SCHEMBL2578998 0.85 GHSR (0.73) GHSRPOLBALDH1A1
Hydrochloric Acid SCHEMBL29440072 0.84 GHSR (0.98) GHSRPOLB
Hydrochloric Acid SCHEMBL17042306 0.84 GHSR (0.98) GHSRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2389941-A1 Growth-hormone secretagogues Elixir Pharmaceuticals, Inc. (US) 2011-11-30 EP disclosed
US-20080261873-A1 Growth-Hormone Secretagogues ELIXIR PHARMACEUTICALS, INC. (US) 2008-10-23 US disclosed
EP-1781311-A2 GROWTH-HORMONE SECRETAGOGUES Elixir Pharmaceuticals, Inc. (US) 2007-05-09 EP disclosed
WO-2006023608-A2 GROWTH-HORMONE SECRETAGOGUES ELIXIR PHARMACEUTICALS, INC. (US) 2006-03-02 WO disclosed
EP-1105376-B1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMA (JP) 2005-02-09 EP disclosed
US-6576656-B1 Such as 1-(2-diethylaminoethyl)-4-trifluoromethyl-6-carbamoyl-3-hydroxy-3-(2 -chlorophenyl)oxindole; growth hormone releaser SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2003-06-10 US disclosed
EP-1105376-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-06-13 EP disclosed
WO-2000010975-A1 OXINDOLE DERIVATIVES AS GROWTH HORMONE RELEASERS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261873-A1 Growth-Hormone Secretagogues GHSR, GHRHR, GIPR GHSR 1/4885TP53 4627/4885POLB 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.